Could Urology’s Antimicrobial Stewardship Be Enhanced by the Routine Use of the Meares and Stamey Test?
Open Access
- 14 April 2025
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 15 (8) , 1002
Abstract
Background/Objectives: Chronic bacterial prostatitis (CBP) is a prevalent urological condition significantly impacting patients’ quality of life. Accurate diagnosis is essential to differentiate bacterial from non-bacterial prostatitis and to guide appropriate antimicrobial therapy. In the context of antimicrobial resistance (AMR), the Meares and Stamey (M&S) test is a valuable diagnostic tool for targeted antibiotic use and a valuable antimicrobial stewardship (AMS) measure. Despite its clinical relevance, its adoption is limited by practical and logistical challenges. Methods: Relevant databases were searched by using methods recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The keywords used included “Meares and Stamey test,” “antimicrobial stewardship and prostatitis,” and “chronic bacterial prostatitis and Meares.” Results: We enclosed seven studies: one single-center prospective observational comparative study, two national surveys, three cross-sectional studies, and one consensus conference. The M&S test remains the gold standard for diagnosing CBP, offering high specificity in identifying bacterial infections localized within the prostate. The test enables precise pathogen identification and facilitates targeted antimicrobial therapy. Despite its clinical relevance, its adoption is hindered by procedural complexity, patient discomfort, and the apparent need for specialized personnel and facilities. Alternative diagnostic methods, such as the two-glass pre- and post-massage test (PPMT), have demonstrated comparable diagnostic sensitivity while being more practical and time-efficient. Additionally, emerging microbiological techniques are under investigation to increase the M&S test’s sensitivity. Conclusions: The M&S test plays a crucial role in AMS by ensuring targeted antimicrobial therapy in CBP. Overcoming its limitations through patient stratification, clinician education, and the integration of emerging microbiological techniques is essential to enhance its applicability in modern urological practice.Keywords
This publication has 33 references indexed in Scilit:
- How I manage bacterial prostatitisClinical Microbiology and Infection, 2022
- Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines PanelEuropean Urology, 2017
- The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort studyWorld Journal of Urology, 2013
- Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitisJournal of Microbiology, 2011
- Chronic Prostatitis/Chronic Pelvic Pain SyndromeUrologic Clinics of North America, 2008
- Biofilm Formation in Uropathogenic Escherichia coli Strains: Relationship With Prostatitis, Urovirulence Factors and Antimicrobial ResistanceJournal of Urology, 2007
- How Does the Pre-Massage and Post-Massage 2-Glass Test Compare to the Meares-Stamey 4-Glass Test in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome?Journal of Urology, 2006
- Recommendations for the evaluation of patients with prostatitisWorld Journal of Urology, 2003
- NIH Consensus Definition and Classification of ProstatitisJAMA, 1999
- Diagnosis and treatment of 409 patients with prostatitis syndromesUrology, 1993